The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer by Qing Qu et al.
WORLD JOURNAL OF 
SURGICAL ONCOLOGY 
Qu et al. World Journal of Surgical Oncology 2014, 12:93
http://www.wjso.com/content/12/1/93RESEARCH Open AccessThe importance of biopsy in clinically diagnosed
metastatic lesions in patients with breast cancer
Qing Qu1, Yu Zong2, Xiao-chun Fei3, Xiao-song Chen2, Cheng Xu1, Gu-yin Lou1 and Kun-wei Shen2*Abstract
Background: Receptor status discordance, such as estrogen receptor (ER), progesterone receptor (PR) and human
epidermal growth factor receptor 2 (HER2) status between primary breast cancer and metastatic lesions has been
reported. The aim of this study was to evaluate the biopsy of clinically diagnosed metastatic lesions and to
determine the changes in hormonal receptor and HER2 status of the metastatic lesions.
Methods: Sixty-three patients with clinically diagnosed metastatic breast cancer underwent an excisional biopsy or
core needle aspiration guided by computed tomography/ultrasound. ER, PR and HER2 were assessed by
immunohistochemistry (IHC).
Results: A total of 48 metastases (76.2%) and nine second primary malignancies (14.3%, seven primary lung cancers
and two primary pancreatic cancers) were found. The discrepancies between ER, PR and HER2 status between the
primary breast cancer and metastatic lesions were 14.6%, 16.7% and 8.3%, respectively. Six lesions (9.5%) were
proved benign upon biopsy.
Conclusions: The biopsy of clinically suspicious metastatic lesions could histologically confirm the diagnosis of
metastasis, evaluate discrepancies between ER, PR and HER2 status and exclude secondary malignancy, which
might change the therapeutic strategy for breast cancer patients.
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Breast cancer is the most common malignancy affecting
women in developed countries. In several cities in China,
the incidence has increased dramatically over the past
30 years [1]. Breast cancer patients with early stage
disease can be cured, although more than 20% of these
patients will eventually develop incurable metastatic
disease [2,3]. However, the rates of disease-free survival
and the overall survival have increased over the years,
largely because adjuvant therapy (chemotherapy, radi-
ation therapy or hormone therapy), has helped prevent
local and distant failures. The estrogen receptor (ER),
progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) are important indica-
tors to determine the prognosis of patients with breast
cancer. Breast cancers can be classified into five subtypes* Correspondence: kwshenrj@163.com
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unless otherwise stated.according to the ER, PR, HER2 and other markers:
luminal A, luminal B, normal breast-like, basal-like, and
HER2 overexpressing tumors. ER, PR and HER2 are
essential in determining the use of hormone therapy,
chemotherapy and targeted therapy [4-7].
Metastasis is the most frequent reason for treatment
failure in breast cancer. Diagnosis of metastasis or relapse
usually depends on clinical, biological and radiologic evi-
dence [8]. In the metastatic setting, the characteristics of
the primary tumors, such as ER, PR and HER2 status, are
important to determine the choice of therapeutic strategy.
Oncologists often use primary tumor biomarkers to
choose endocrine therapy, chemotherapy or targeted ther-
apy for metastatic disease. However, in the last few years,
several studies have demonstrated a significant discord-
ance between hormone receptor (HR) status and HER2
status between primary breast cancer and paired asyn-
chronous metastasis [9-13]. If these therapy-predictive
markers change throughout tumor progression, then in-
vestigating metastatic lesions would provide additional. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of biopsied patients
Characteristics n = 63 (%)
Age (years) 53.1 (30 to 73)


























Location of suspicious lesions
Visceraa 48 (76.2%)
Soft tissuesb 15 (23.8%)
Number of suspicious lesions
Single 11 (17.5%)
Multiple 52 (82.5%)
Abbreviations: IDC, invasive ductal carcinoma, RFS, relapse free survival, TNBC,
triple negative breast cancer, aViscera: liver, pleura, lung, and ovary;
bSoft tissues: lymph node and soft tissue.
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enable better management of patients with advanced
disease. Due to new therapies, such as targeted therapy
and new endocrine therapies, selection of patients using
this additional information is crucial for increasing clinical
benefit and avoiding unnecessary treatment and toxicities.
The aim of this retrospective study was to investigate
the changes in ER, PR and HER2 status in metastatic
lesions compared with paired primary breast cancer, and
to find changes in the treatment strategies after biopsy
confirmation of recurrence with assessment of predictive




A total of 63 patients were diagnosed and treated in the
Comprehensive Breast Health Center of Ruijin Hospital,
Shanghai Jiaotong University School of Medicine, Shang-
hai, China between September 2009 and December
2012. Patients who met the following criteria were con-
sidered for further analysis: (1) primary breast cancer
totally resected, (2) metachronous lesions with suspected
metastasis detected by physical examination, ultrasound
or computed tomography (CT) without evidence of pri-
mary tumor recurrence, (3) multidisciplinary decision
for biopsy by surgeons, medical oncologists, radiation
therapists, radiologists and pathologists, and (4) complete
clinical and follow-up data. Ultimately, 63 patients met
the inclusion criteria and were selected for this study.
The metastatic histological assessment could be made
at metastatic lesion presentation or later after the com-
pletion of several lines of treatment. Patients who only
underwent cytological investigation of metastasis were
excluded from the study.
Methods
Tissue specimens were obtained by excisional biopsy or
core needle aspiration biopsy under guidance of ultra-
sound or CT. A representative section of the tumor
specimen from each case was selected and stained
immunohistochemically with a panel of antibodies
including ER, PR and HER2. Routine H&E-stained
sections were reviewed for the histological tumor type.
Immunohistochemistry (IHC) staining was performed
on formalin-fixed, paraffin-embedded tissues to evaluate
ER, PR and HER2 status. The anti-ER antibody and anti-
PR antibody were both from DAKO (Carpinteria, CA,
USA). Positive staining for ER/PR was defined as nuclear
staining in more than 1% of tumor cells. The anti-HER2
antibody was from Roche (Basel, Switzerland). HER2
was evaluated by an experienced pathologist and scored
as 0, 1+, 2+, and 3+ according to the American Society
of Clinical Oncology/College of American Pathologists(ASCO/CAP) guidelines. HER2 negativity was consid-
ered as HER2 0 or 1+, whereas cases with 2+, or 3+
would be tested using fluorescence in situ hybridization
(FISH). An amplification ratio HER2/C-17 of > 2 on
FISH test was considered as HER2 positivity.
Results
Clinical characteristics of patients
Table 1 summarizes the clinical characteristics of the bi-
opsied patients. The median age at breast cancer
Table 3 Change in estrogen receptor and progesterone
receptor (ER/PR) and human epidermal growth factor
receptor 2 (HER2) status in primary and metastatic
tumors
Primary tumor Metastatic lesions Case number
ER - ER + 2
ER + ER - 5
PR - PR + 1
PR + PR - 7
HER2 - HER2 + 2
HER2 + HER2 - 2
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patients had invasive ductal histology (98.4%), and most
primary tumors were the luminal subtype.
Table 2 summarizes the biopsy characteristics in these
patients. Most patients had undergone biopsy of the
lung (38.1%), and the most frequent guidance was using
CT (61.9%).
Receptor expression discordance between primary breast
cancer and metastatic lesions
Overall, 48 metastases (76.2%) were confirmed through
biopsy. ER and PR status changed between the primary
breast tumor and metastatic lesions in 14.6% and 16.7%
of patients, respectively (Table 3). There were only four
(8.3%) cases that showed a discrepancy in HER2 status
(Figure 1). According to the HR and HER2 status of the
metastatic lesions, the choice of treatment for the pa-
tients was determined at a multidisciplinary treatment
meeting. The treatment for the patients without any
discrepancy between the primary tumor and metastatic
lesions was chosen according to the characteristics of
the primary tumors. For the patients with a discrepancy
between HR and HER2 status, fourteen patients received
modified therapeutic strategies, including ten hormone
therapies and four targeted therapies due to a switch in
receptors status.
Second primary malignancy
In our study, a second primary malignancy was defined as
one with a different histological type or different compo-
nents external to the breast. Nine second primary malig-
nancies (14.3%) were diagnosed upon biopsy, including
seven primary lung cancers (Figure 2) and two primary
pancreatic cancers.Table 2 Characteristics of rebiopsies
Characteristics n = 63 (%)
Site of rebiopsy
Lung 24 (38.1%)
Chest wall 12 (19.0%)
Liver 9 (14.3%)
Lymph nodes 12 (19.0%)
Pancreas 2 (3.2%)







Incision 8 (12.7%)Benign lesion
Six patients (9.5%) did not have any evidence of relapse
or metastasis upon biopsy. These patients were followed
every three months and to date have shown no disease
progression.
Discussion
Breast cancer threatens womens’ health all over the
world. Breast cancer is now the second most common
malignancy in China [14]. Nearly one half of these pa-
tients will eventually develop metastases. In the meta-
static setting, the choice of systemic treatment is often
based on the biomarker characteristics of the primary
tumor, including ER, PR and HER2 status. The breast
cancer subtypes defined by ER, PR, and HER2 are help-
ful to direct treatment and choose endocrine therapy,
molecular-targeted therapy and cytotoxic chemotherapy.
Firstly, our study shows that ER, PR, and HER2 are
lost and gained in a considerable proportion of patients
throughout tumor progression: loss of ER in five cases,
gain of ER in two cases, loss of PR in seven cases, gain
of PR in one case, loss of HER2 in two cases, and gain of
HER2 in two cases. Several studies have also demon-
strated the discordance between the primary tumor and
metastatic lesions in recent decades [10,13,15,16]. Pub-
lished studies have found discordance rates for ER status
ranging from 10.2 to 56%, PR status ranging from 24.8
to 48.6%, and HER2 status ranging from 2.9 to 16%
[15-23]. Jenson’s study has shown that ER status of the
metastases changed in 12 to 13% of cases, and HER2
status changed in 5 to 8% [17]. ER/PR and HER2 sta-
tuses may be modified by treatment or during disease
progression. Liu et al. reported that in asynchronous
liver metastases, the change in ER, PR and HER2 was
30.4%, 54.3% and 10.9%, respectively. However, in syn-
chronous liver metastases, the change in ER, PR and
HER2 were 0, 33.3% and 8.3% respectively [18]. Lind-
strom and colleagues demonstrated that one in three pa-
tients with breast cancer experience alteration of HR
status, and 15% of patients experience a change in HER2
status during tumor progression. In addition, they found
Figure 1 Microscopic findings of HER2 in (A) primary breast tumor (FISH-, magnification x 1,250); (B) liver metastasis (FISH+,
magnification x 1,250).
Qu et al. World Journal of Surgical Oncology 2014, 12:93 Page 4 of 6
http://www.wjso.com/content/12/1/93that patients with ER-positive primary tumors that chan-
ged to ER-negative metastases had an increased mortal-
ity risk compared with patients with stable ER-positive
tumors. The understanding of tumor dissemination by
clarifying the instability of clinically used tumor markers
throughout tumor progression could be used to infer
both biologic and therapeutic implications in the meta-
static setting [19]. The discordance of ER and HER2 in
the relapse setting would introduce additional thera-
peutic choices. The clinical implication of this discord-
ance is important, the loss of HR and HER2 generally
indicates resistance to endocrine therapy and trastuzu-
mab, respectively and therefore these patients would
benefit from a change of treatment strategy. A total ofFigure 2 Microscopic findings of (A) primary tumor (magnification x 2
primary lung cancer (IHC TTF-1+, magnification x 200).14 patients required modification of their treatment
strategies in our study, including hormone therapy and
targeted therapy because of the altered characteristics in
metastatic lesions. Seven patients received endocrine
therapy because of the switch of hormone receptor from
negative to positive; three patients received chemother-
apy because of the negative hormone receptor status in
the metastatic lesions which most likely indicates a re-
sistance to endocrine therapy. Two patients were eligible
for treatment with trastuzumab because of HER2 status
switch to positive; two patients did not use trastuzumab
in case of negativity of HER2 in metastatic lesions which
probably means a resistance to trastuzumab. Since
tumor instability is seen throughout tumor progression,00), (B) site of lung lesion (magnification x 200); and (C) site of
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biopsies in a consecutive manner in the advanced setting
to optimize clinical decision-making for the patient.
There are several explanations for these alterations.
The characteristics of the metastatic lesions could be
influenced by factors such as clonal selection by micro-
environment and clonal changes induced by adjuvant
therapies [24-26]. Additionally, certain factors can influ-
ence the IHC results. In the process of IHC staining,
many factors could affect results such as fixation time,
staining methodology and the size of tissue blocks [27].
Therefore, according to the European Society for Med-
ical Oncology (ESMO) guideline, a biopsy should be per-
formed if there is one single lesion, as well as when the
patient has a history of more than one cancer, and when
there is suspicion of an alternative diagnosis [28].
Secondly, we found nine second primary malignancies
external to the breast through the biopsy of clinically
diagnosed metastatic lesions. A number of studies have
reported that patients with breast cancer have a high risk
of developing a second malignancy, with standardized
incidence ratios (SIRs) ranging from 1.15 to 1.6 [29-32].
Brown et al. calculated that the SIR for second cancers
was 1.15 in patients with a history of breast cancer [29].
Kirova et al. reported that the SIR of the primary lung
cancer in French patients with a history of the breast
cancer is 1.2, but this finding was not significant [30].
Our observation of an increased risk of second primary
lung cancer confirms previous findings. Rena et al.
reported that for a single lung lesion in patients with
breast cancer, the rate of primary lung cancer and lung
metastasis was 48.1% and 34.2%, respectively [33]. Jensen
et al. also showed that biopsies of the suspicious meta-
static lesions were benign disease or other malignancies
in 14% of the patients [17]. In our research, all seven pa-
tients with primary lung cancers, confirmed by core nee-
dle biopsy, finally had surgery or chemotherapy for the
lung cancer. The mechanism involved in the develop-
ment of second malignancy has not been fully identified.
It may be related to the treatment of the breast cancer,
such as radiation therapy and anti-estrogen therapy
[29,30,34-36].
Thirdly, in our study six patients had a confirmed benign
lesion through rebiopsy. The pathologists did not find any
evidence of metastasis. These six patients have received
regular follow-up every three months. In their study, Rena
et al. also reported the rate of the benign lesion of single
lung lesion after breast surgery was 17.7% [33].
There are several limitations inherent in this study.
This analysis was based on a single-center, retrospective
study, and therefore we are planning to design prospect-
ive studies in the future. In addition, the database spans
a short time period (2009 to 2012), during which there
has not been enough follow-up data to determine therelationship between the prognosis and the discrepancies
of ER, PR and HER2 status.
Conclusions
In summary, biopsy of suspicious lesions can confirm the
relapse of the tumor, exclude the second primary tumor,
identify the status of ER, PR and HER2, and allow some
patients with breast cancer to benefit from hormone ther-
apy and/or anti-HER2 treatment. The discordance in ER
and PR receptor expression between the primary breast
tumor and the corresponding metastatic lesions is high,
whereas HER2 status remains relatively constant. Thera-
peutic strategies could be changed after the biopsy be-
cause of changes in the tumor characteristics and,
therefore, the patients could receive the most effective
treatment and avoid unnecessary toxicity. We recommend
that biopsy of suspicious metastases and reassessment of
ER, PR and HER2 status should become a routine proced-
ure in the treatment of breast cancer patients.
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